These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21288201)

  • 21. Myeloproliferative neoplasms (MPNs).
    Godfrey AL
    Blood Rev; 2020 Jul; 42():100717. PubMed ID: 32527564
    [No Abstract]   [Full Text] [Related]  

  • 22. Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms.
    Guglielmelli P; Bartalucci N; Rotunno G; Vannucchi AM
    Expert Rev Hematol; 2014 Aug; 7(4):423-5. PubMed ID: 24849893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Not just clonal expansion of hematopoietic cells, but also activation of their progeny in the pathogenesis of myeloproliferative disorders.
    Cazzola M; Passamonti F
    Haematologica; 2006 Feb; 91(2):159. PubMed ID: 16461298
    [No Abstract]   [Full Text] [Related]  

  • 24. [Management strategy for BCR-ABL negative myeloproliferative neoplasms].
    Gotoh A; Komatsu N
    Rinsho Ketsueki; 2014 Jan; 55(1):56-65. PubMed ID: 24492037
    [No Abstract]   [Full Text] [Related]  

  • 25. How We Treat Myeloproliferative Neoplasms.
    Harrison CN; McLornan DP; Francis YA; Woodley C; Provis L; Radia DH
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S19-26. PubMed ID: 26297273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation.
    Pingali SR; Mathiason MA; Lovrich SD; Go RS
    Clin Lymphoma Myeloma; 2009 Oct; 9(5):E25-9. PubMed ID: 19858050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of myeloproliferative diseases].
    Burkhardt R
    Munch Med Wochenschr; 1973 May; 115(19):878-91. PubMed ID: 4800219
    [No Abstract]   [Full Text] [Related]  

  • 28. Chronic myeloproliferative diseases.
    de Lacerda JF; Oliveira SN; Ferro JM
    Handb Clin Neurol; 2014; 120():1073-81. PubMed ID: 24365372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Summary of recommendations for the diagnosis and therapy of BCR/ABL-negative myeloproliferation of the Czech Working Group for Ph-negative myeloproliferative disease (CZEMP) of the Czech Hematologic Society CLS JEP ].
    Penka M; Schwarz J; Campr V; Pospíšilová D; Křen L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulíček P; Jonášová A; Kissová J; Kořístek Z; Schützová M; Vonke I; Walterová L;
    Vnitr Lek; 2012 Feb; 58(2):163-8. PubMed ID: 22463098
    [No Abstract]   [Full Text] [Related]  

  • 30. Introduction to a review series on myeloproliferative neoplasms.
    Cazzola M
    Blood; 2017 Feb; 129(6):659. PubMed ID: 28028028
    [No Abstract]   [Full Text] [Related]  

  • 31. Therapeutic options for leukemic transformation in patients with myeloproliferative neoplasms.
    Khan M; Siddiqi R; Gangat N
    Leuk Res; 2017 Dec; 63():78-84. PubMed ID: 29121538
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cellular mechanisms of myeloproliferative disorders.
    Ogawa M
    Br J Haematol; 1984 Dec; 58(4):563-5. PubMed ID: 6518132
    [No Abstract]   [Full Text] [Related]  

  • 33. Circulating progenitor cells in chronic myeloproliferative diseases.
    Rosti V; Massa M
    Haematologica; 2006 Nov; 91(11):1445-7. PubMed ID: 17082003
    [No Abstract]   [Full Text] [Related]  

  • 34. An atypical myeloproliferative disorder with t(8;13) (p11;q12): a third case.
    Macdonald D; Sheerin SM; Cross NC; Spencer A; Goldman JM
    Br J Haematol; 1994 Apr; 86(4):879-80. PubMed ID: 7918089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myeloproliferative neoplasms.
    Kim J; Haddad RY; Atallah E
    Dis Mon; 2012 Apr; 58(4):177-94. PubMed ID: 22449367
    [No Abstract]   [Full Text] [Related]  

  • 36. Inclusion of secondary chronic myelomonocytic leukemia and myeloproliferative disease, unclassifiable, in classification of pediatric myeloproliferative disorders.
    Occhipinti E; Correa H; Yu L; Craver R
    J Pediatr Hematol Oncol; 2006 Oct; 28(10):700-1. PubMed ID: 17023836
    [No Abstract]   [Full Text] [Related]  

  • 37. [Approach to diagnosis and management of myeloproliferative neoplasm variants].
    Mitsumori T; Kirito K
    Rinsho Ketsueki; 2015 Aug; 56(8):963-71. PubMed ID: 26345554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myelodysplastic syndrome evolving into a myeloproliferative disorder: one disease or two?
    Verhoef GE; Demuynck H; Zachee P; Boogaerts MA
    Leukemia; 1994 Apr; 8(4):714-5. PubMed ID: 8152271
    [No Abstract]   [Full Text] [Related]  

  • 39. Myeloproliferative disorders: premalignant, stem cell, G1 diseases?
    Lelièvre H; Ferrand A; Mozziconacci MJ; Birnbaum D; Delaval B
    Leukemia; 2006 Sep; 20(9):1475-80. PubMed ID: 16810200
    [No Abstract]   [Full Text] [Related]  

  • 40. Myelodysplastic/myeloproliferative disorders.
    Malcovati L; Cazzola M
    Haematologica; 2008 Jan; 93(1):4-6. PubMed ID: 18166777
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.